Chemo plus radiation for advanced pancreatic cancer with normal CA19-9
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have a type of pancreatic cancer called adenocarcinoma that has spread or is locally advanced and has stopped responding to at least one chemotherapy treatment.
- You have not had radiation therapy for your cancer before.
- Your blood tests for tumor markers (CA19-9, CEA, and CA125) are within normal ranges.
- You have at least one tumor that can be measured on imaging scans, and your overall health is good enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial tests a precise type of radiation therapy guided by MRI for people with locally advanced pancreatic cancer. It aims to treat the tumor while protecting nearby healthy tissue, potentially improving outcomes after chemotherapy.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
This trial combines focused radiation with a chemotherapy drug combo to help shrink or control locally advanced pancreatic cancer. If it works, this treatment might make the tumor smaller and improve quality of life.
This Phase 2 study tests whether FOLFIRINOX given after pancreatic surgery can lower the chance the cancer comes back. It focuses on people with pancreatic ductal adenocarcinoma who had their tumor completely removed and have no spread to distant organs.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.